Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Purple Biotech American Depositary Shares Representing 200 Ord Shs PPBT

Healthcare
Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi... see more

Recent & Breaking News (NDAQ:PPBT)

Kitov Announces Pricing of $6.0 Million Public Offering

GlobeNewswire March 12, 2020

Kitov Pharma Expands Planned NT-219 Clinical Program for Difficult to Treat Cancers

GlobeNewswire February 24, 2020

Kitov Pharma Provides Corporate Update and Reports Full-Year 2019 Financial Results

GlobeNewswire February 11, 2020

Kitov Pharma Receives Issue Notification for a U.S. Patent Covering its anti-CEACAM1 Cancer Drug, CM-24

GlobeNewswire February 3, 2020

Kitov Pharma Receives Notice of Intention to Grant European Patent Covering the Use of NT-219 in Combination with EGFR Inhibitors

GlobeNewswire January 24, 2020

Kitov Pharma Announces Appointment of Bertrand Liang, M.D., Ph.D., as Chief Medical Officer

GlobeNewswire January 9, 2020

Kitov Pharma Announces Closing of FameWave Acquisition

GlobeNewswire January 8, 2020

Kitov Pharma Granted Additional 180-day Extension by Nasdaq to Comply with Bid Price Rule

GlobeNewswire January 8, 2020

Kitov Pharma Announces Amended Marketing and Distribution Agreement with Coeptis and Provides Update on the Upcoming Launch of Consensi(TM) in the U.S

GlobeNewswire October 11, 2019

Kitov Pharma Appoints Eric K. Rowinsky, M.D., as Chairman of its Board

GlobeNewswire October 2, 2019

Kitov Pharma Presents Newly Released Data for NT-219 in Reversing Pancreatic Cancer Drug Resistance

GlobeNewswire September 9, 2019

Kitov Pharma to Present at the H.C. Wainwright 21st Annual Healthcare Conference

GlobeNewswire September 3, 2019

Kitov Pharma to Present New Data on NT-219 Targeting Cancer Drug Resistance at the AACR Pancreatic Cancer: Advances in Science and Clinical Care Conference

GlobeNewswire August 29, 2019

Kitov Pharma Announces Significant Progress in Closing of FameWave Acquisition Deal

GlobeNewswire August 16, 2019

Administrative Enforcement Agreement Finalized between Kitov Pharma and the Israeli Securities Authority

GlobeNewswire August 14, 2019

Kitov Pharma Reports First Half 2019 Financial Results and Provides Business Update

GlobeNewswire August 8, 2019

Kitov Receives Nasdaq Notification Regarding Minimum Bid Requirements

GlobeNewswire July 12, 2019

Kitov Successfully Completes IND-enabling Studies to advance NT219 for the Treatment of Patients with Recurrent or Metastatic Head and Neck Cancers

GlobeNewswire June 27, 2019

Kitov Receives Notice of Allowance for Additional U.S. Patent Covering its Commercial Product Consensi(TM)

GlobeNewswire May 10, 2019

Kitov to Present Clinical Development Plan for Oncology Candidate NT-219 at the 18th MIXiii-BIOMED Conference

GlobeNewswire May 9, 2019